Jefferies puts Keryx at buy

Keryx Biopharmaceuticals Inc. was given a buy rating by Jefferies & Co., Inc. analyst Adam Walsh. Jefferies said it is encouraged by the in-licensing of Zerenex, believing it is complementary to KRX-101, with a large market potential. The analyst gives Keryx a 12- to 18-month price target of $20. Shares of the New York City pharmaceutical company were up 70 cents, or 4.58%, at $16.00 on volume of 587,455 shares versus the three-month running average of 354,311 shares. (Nasdaq: KERX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.